Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Daiichi Sankyo on Path to Net 2 Trillion Yen in Sales by FY2025 on Robust Core Products
Daiichi Sankyo saw its sales expand 22.4% over the year in FY2022 propelled by the growth of its cancer drug Enhertu (trastuzumab deruxtecan) and other mainstay products. Fueled by strong performance, the company projects its sales to reach as much…
To read the full story
Related Article
- Daiichi Sankyo’s Profit Down on HER3-DXd Delay, One-Off CMO Costs
November 4, 2025
- Daiichi Sankyo Plays Down Tariff Impact for FY2025, Eyes US Production Boost
August 1, 2025
- Daiichi Sankyo Marks 2-Digit Growth in Sales, Net Profit Driven by Enhertu
April 28, 2025
- Daiichi Sankyo Ups Outlook on Earnings Growth Driven by Enhertu
November 1, 2024
- Daiichi Sankyo’s Q1 Sales Grow 24% as Mainstays Fare Well
August 1, 2024
- Daiichi Sankyo Ups FY2025 Sales Goal to 2.1 Trillion Yen on Bullish Cancer Biz
April 26, 2024
- Daiichi Sankyo Ups Full-Year Outlook on Growth of Flu, COVID Products
February 1, 2024
- Daiichi Sankyo’s H1 Sales Jump 19.5% on Robust Global Products
November 1, 2023
- Daiichi Sankyo Enjoys Rosy Q1 Earnings on Strong Mainstays
August 1, 2023
- Daiichi Sankyo’s Revenue Up 16.9% in April-December on Buoyant Mainstays
February 1, 2023
- Daiichi Sankyo Nets Double-Digit Rise in H1 Sales as Major Products Fare Well
November 1, 2022
- Daiichi Sankyo Q1 Sales Rise 6.2% on Robust Enhertu Performance, Weaker Yen
August 1, 2022
- Daiichi Sankyo Breaks 1 Trillion Mark in FY2021 Sales on Bullish Enhertu, Lixiana
April 28, 2022
- Daiichi Sankyo’s Revenue Rises 9.8% in April-December on Upbeat Mainstays
February 1, 2022
- Daiichi Sankyo’s 1st Half Operating Profit Jumps 44.9% Thanks to Lixiana, Enhertu
November 1, 2021
- Daiichi Sankyo’s Q1 Sales Surge on Upbeat Global Brands
August 2, 2021
- Daiichi Sankyo Sales Slip in FY2020 as Price Cuts, Deal Termination Weigh
April 28, 2021
- Daiichi Sankyo’s Revenue Down 2.4% in April-December as Mainstays Flounder at Home
February 1, 2021
- Daiichi Sankyo’s 6-Month Operating Profit Falls 32% on Higher SGA Costs for Enhertu, ADC R&D Spending
November 2, 2020
- Daiichi Sankyo Sales Skid 4.9% on Coronavirus, Price Cuts; Enhertu, Edoxaban Upbeat
August 3, 2020
BUSINESS
- FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
- Nxera Gets US$1.8 Million Early-Stage Milestone from Centessa
February 13, 2026
- Nxera Licenses GPCR Program to European VC-Backed Startup
February 13, 2026
- Alfresa Launches Neffy Nasal Spray for Anaphylaxis in Japan
February 13, 2026
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…